No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.
Katherine M RobinsonWenjian YangSeth E KarolNancy KornegayDennis JayCheng ChengJohn K ChoiDario CampanaChing-Hong PuiBrent WoodMichael J BorowitzJulie Gastier-FosterEric C LarsenNaomi WinickWilliam L CarrollMignon L LohElizabeth A RaetzStephen P HungerMeenakshi DevidasElaine R MardisRobert S FultonMary V RellingSima JehaPublished in: Pediatric blood & cancer (2019)
We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL.